Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
Most Recent Events
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 10 Aug 2022 Status changed from active, no longer recruiting to completed.
- 05 Oct 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.